Redwoods Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York.
IPO Year: 2022
Exchange: NASDAQ
Website: https://www.redwoodscorporation.com
25-NSE - Redwoods Acquisition Corp. (0001907223) (Subject)
425 - Redwoods Acquisition Corp. (0001907223) (Subject)
8-K - Redwoods Acquisition Corp. (0001907223) (Filer)
425 - Redwoods Acquisition Corp. (0001907223) (Subject)
8-K/A - Redwoods Acquisition Corp. (0001907223) (Filer)
425 - Redwoods Acquisition Corp. (0001907223) (Subject)
8-K - Redwoods Acquisition Corp. (0001907223) (Filer)
10-Q - Redwoods Acquisition Corp. (0001907223) (Filer)
NT 10-Q - Redwoods Acquisition Corp. (0001907223) (Filer)
425 - Redwoods Acquisition Corp. (0001907223) (Subject)
Shares of Super Micro Computer, Inc. (NASDAQ:SMCI) fell sharply during Friday's session. The company announced its third-quarter earnings date and did not provide preliminary estimates as it did with the second quarter. Super Micro Computer shares dipped 13.2% to $806.00 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Next.e.GO N.V. (NASDAQ:EGOX) shares jumped 129% to $0.0817. Redwoods Acquisition Corp. (NASDAQ:RWOD) shares rose 62.5% to $12.03 after falling around 3% on Thursday. Zhongchao Inc. (NASDAQ:ZCMD) gained 50% to $2.16 after gaining over 7% on Thursday. Ault Alliance, Inc. (NYSE:AULT) surged 46% to $0.3544 after the company
Redwoods Acquisition Corp. (NASDAQ:RWOD) shares traded higher on Friday after the company announced that shareholders had approved its merger agreement with Anew Medical. Following the consummation of the transactions, Redwoods will change its name to Anew Medical, the company said in an exchange filing (April 18). On May 30, 2023, Redwoods Acquisition entered into a business combination agreement with Anew Medical Sub, Inc. The transaction values the combined company at a pro forma enterprise value of approximately $94.0 million, with existing ANEW stockholders rolling over 100% of their equity into the combined company. The transaction is expected to provide approximately $54
NFLX: -7% | Netflix shares are trading lower after the company reported Q1 financial results. CNS: 7% | Cohen & Steers shares are trading higher after it was announced the stock will join the S&P SmallCap 600. RWOD: 217% | Redwoods Acquisition shares are trading higher after the company announced that shareholders approved its merger agreement with Anew Medical.
-8-K
Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results. Wang & Lee Group posted a FY23 loss of 2 cents per share, versus a year-ago loss of 5 cents per share. The company's revenue came in at $6.83 million versus, $4.17 million in the year-ago period, according to data from Benzinga Pro. Wang & Lee Group shares jumped 37.7% to $0.7220 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Redwoods Acquisition Corp. (NASDAQ:RWOD) shares gained 141% to $17.83 in pre-market trading after falling around 3% on Thursday. Zhongchao Inc
ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. In May 2023, ANEW announced its proposed merger with a special purpose acquisition company ("SPAC") called Redwoods (NASDAQ:RWOD).
The transaction values the combined company at a pro forma enterprise value of approximately $94.0 million (assuming no redemptions) with existing ANEW stockholders rolling over 100% of their equity into the combined company. The transaction is expected to provide approximately $54 million of cash proceeds, assuming no redemptions by Redwoods stockholders. Upon completion of the transaction, the combined company will operate as ANEW MEDICAL and expects to remain listed on NASDAQ.
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
SC 13G - Redwoods Acquisition Corp. (0001907223) (Subject)
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
SC 13G/A - Redwoods Acquisition Corp. (0001907223) (Subject)
NEW YORK, June 24, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or the "Company") announces the Company's common shares and warrants will begin trading on the NASDAQ Global Market under the ticker symbols "WENA" and "WENAW", respectively. ANEW is a specialty pharmaceutical company specializing in the advancement of diagnostics and novel disease-modifying therapies for neurological and age-related disorders. Dr. Joseph Sinkule, Founder and CEO of ANEW, commented, "Today marks our first day as a publicly traded company and as a dedicated leader in the development of novel disease-modifying therapies for neurological and age-related disorders. We're a relatively new company but our manageme
ANEW MEDICAL, INC.'s shares and warrants are expected to begin trading on the Nasdaq Global Market under the tickers "WENA" and "WENAW", respectively. NEW YORK, NY, June 21, 2024 (GLOBE NEWSWIRE) -- ANEW MEDICAL, INC. ("ANEW" or the "Company"), a biopharmaceutical technology company focused on developing disruptive new therapies to treat the central nervous system ("CNS") and neurodegenerative diseases, and Redwoods Acquisition Corp. (NASDAQ: RWOD) ("RWOD"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The combined company will be named "ANEW MEDICAL, INC." a
NEW YORK, March 4, 2024 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or "the Company") (OTCPK: LEAS) a US-based biotechnology company ("ANEW") focused on developing cell and gene- based treatments to affect aging and age-related diseases, announced that is has been granted and issued a patent in China, number CN 117126829 A for the use of ANEW's Klotho protein and Klotho gene delivery and expression systems in the treatment of cognition, memory and neurodegenerative diseases. This intellectual property was licensed by ANEW from UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) and INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS (ICREA) in Barcelona, Spain on an exclusive worldwide basis and ANEW paid
ANEW MEDICAL is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurodegenerative diseases.ANEW MEDICAL intends to use the proceeds from the merger transaction to progress its lead gene therapy programs including for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).NEW YORK, June 6, 2023 /PRNewswire/ -- ANEW MEDICAL, INC. (OTC:LEAS), an early-stage biotechnology company focused on developing disruptive new therapies to treat age-related neurodegenerative diseases, previously announced that it has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ:RWOD, ", Redwoods", )))
NEW YORK, May 31, 2023 /PRNewswire/ -- Redwoods Acquisition Corp. (the "Company") (NASDAQ:RWOD) today announced that it received a delinquency notification letter ("Notice") from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") on May 24, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule") as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2023 (the "Form 10-Q"). The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC"). The Company filed
ANEW MEDICAL, INC. ("ANEW") has entered into a definitive business combination agreement with Redwoods Acquisition Corp. (NASDAQ:RWOD).ANEW is developing a platform and commercializing novel gene therapies to alleviate and/or reverse the progression of neurogenerative diseases.ANEW intends to use the proceeds from the transaction to progress its lead gene therapy programs including for amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD).NEW YORK, May 30, 2023 /PRNewswire/ -- ANEW MEDICAL, INC. ("ANEW" or the "Company"), an early-stage biotechnology company focused on developing disruptive new therapies to treat neurodegenerative diseases, announced today that it has entered into